Track Adaptive Biotechnologies Corporation — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Adaptive Biotechnologies Corporation ADPT · Stock Open Adaptive Biotechnologies Corporation in new tab

26.68 USD
Add to portfolio
EPS
-0.40
P/B
28.11
ROE
-38.76
Beta
2.10
Target Price
25.07 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateNov. 4, 2026
EPS-0.40
Book Value0.90
Price to Book28.11
Debt/Equity272.46
% Insiders1.292%
Growth
Revenue Growth0.22%
Estimates
Forward P/E-136.66
Forward EPS-0.18
Target Mean Price25.07

DCF Valuation

Tweak assumptions to recompute fair value for Adaptive Biotechnologies Corporation (ADPT)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Adaptive Biotechnologies Corporation Logo Adaptive Biotechnologies Corporation Analysis (ADPT)

United States Health Care Official Website Stock

Is Adaptive Biotechnologies Corporation a good investment? Adaptive Biotechnologies Corporation (ADPT) is currently trading at 26.68 USD. Market analysts have a consensus price target of 25.07 USD. This suggests the asset is currently trading above analyst expectations.

Earnings Schedule: Adaptive Biotechnologies Corporation is expected to release its next earnings report on Nov. 4, 2026. The market consensus estimate for Forward EPS is -0.18.

Investor FAQ

Does Adaptive Biotechnologies Corporation pay a dividend?

No, it does not currently pay a dividend.

What asset class is Adaptive Biotechnologies Corporation?

Adaptive Biotechnologies Corporation is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Nov. 4, 2026. The company currently has a trailing EPS of -0.40.

Company Profile

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.

Exchange Ticker
F 1HM.F
NMS (United States) ADPT
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
July 15, 2026 1:4
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion